Autonomix Medical to Implement 1-for-21 Reverse Stock Split
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Source: seekingalpha
- Reverse Stock Split Plan: Autonomix Medical will implement a 1-for-21 reverse stock split on June 24, 2026, which is expected to significantly enhance the stock price per share, thereby improving market perception of its stock.
- Reduction in Shares: Post-split, the outstanding shares will decrease from approximately 11.4 million to about 543,000, a change that will help improve earnings per share metrics and bolster investor confidence.
- Authorized Shares Unchanged: Despite the reduction in outstanding shares, the number of authorized common shares remains at 500 million, indicating that the company still has a substantial amount of unissued shares available for future financing or strategic purposes.
- Continued Nasdaq Trading: After the reverse split, AMIX shares will continue trading on Nasdaq under the same ticker symbol, which will help maintain investor recognition and market stability.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AMIX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AMIX
Wall Street analysts forecast AMIX stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.389
Low
5.00
Averages
5.00
High
5.00
Current: 0.389
Low
5.00
Averages
5.00
High
5.00
About AMIX
Autonomix Medical, Inc. is a medical device company focused on advancing technologies to develop how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity. It is developing its technology for pancreatic cancer and pancreatitis, conditions that can cause debilitating pain and need an effective solution. Its technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Its development efforts are divided into two parts: diagnostic sensing and therapeutic radiofrequency ablation. The Company is developing Autonomix system, which is primarily catheter-based, meaning that its sensing equipment is delivered to its targeted location via a lumen within the body.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Autonomix Medical Announces 1-for-21 Reverse Stock Split
- Reverse Stock Split: Autonomix Medical has announced a 1-for-21 reverse stock split effective June 24, 2026, which will reduce outstanding shares from approximately 11.4 million to about 543,000, thereby increasing the market value per share and potentially boosting investor confidence.
- Trading Details: Post-split, the company's common stock will resume trading on the Nasdaq Capital Market under the existing ticker symbol 'AMIX' with a new CUSIP number 05330T304, ensuring a smooth transition for investors to the new capital structure.
- Shareholder Rights Protection: The split will not change the nominal par value per share, and no fractional shares will be issued; instead, shareholders entitled to fractional shares will receive cash compensation, safeguarding their interests during the transition.
- Innovation Context: Autonomix focuses on advancing innovative treatments for nervous system diseases, and the reverse split is expected to enhance the company's capital structure for future financing and technology development, thereby strengthening its competitive position in the medical device market.
See More
Autonomix Medical to Implement 1-for-21 Reverse Stock Split
- Reverse Stock Split Plan: Autonomix Medical will implement a 1-for-21 reverse stock split on June 24, 2026, which is expected to significantly enhance the stock price per share, thereby improving market perception of its stock.
- Reduction in Shares: Post-split, the outstanding shares will decrease from approximately 11.4 million to about 543,000, a change that will help improve earnings per share metrics and bolster investor confidence.
- Authorized Shares Unchanged: Despite the reduction in outstanding shares, the number of authorized common shares remains at 500 million, indicating that the company still has a substantial amount of unissued shares available for future financing or strategic purposes.
- Continued Nasdaq Trading: After the reverse split, AMIX shares will continue trading on Nasdaq under the same ticker symbol, which will help maintain investor recognition and market stability.
See More
Autonomix Releases Latest CEO Corner Segment Highlighting Clinical Recognition
- Growing Scientific Recognition: Since last fall, Autonomix has secured 13 abstract acceptances, including nine podium and four poster presentations, showcasing its nerve-sensing and transvascular denervation platform's recognition at global medical conferences, enhancing the company's reputation in the medical device sector.
- Award for Innovation: Autonomix received a top Cardiovascular Innovation Award at the Cardiovascular Research Technologies conference, highlighting the novelty, rigor, and potential impact of its technology platform, which further boosts the company's credibility in clinical applications.
- Transformative Treatment Potential: The company's real-time nerve sensing and targeted therapy approach could revolutionize treatment for complex conditions like pancreatic cancer pain, supporting physician adoption, future clinical trials, and strategic partnerships, thereby enhancing market competitiveness.
- Clinical Study Plans: Autonomix plans to conduct a clinical study in the U.S. aimed at addressing diagnostic and treatment challenges in nervous system diseases through its innovative technology, which is expected to create new growth opportunities for the company.
See More
Autonomix Medical Advances Cancer Pain Treatment Insights
- Clinical Data Significance: Autonomix Medical's clinical data presented at the Society of Surgical Oncology Annual Meeting was selected for podium presentation, highlighting its potential clinical impact on visceral cancer pain management, which may transform existing treatment practices.
- Platform Technology Potential: The company's microchip sensing array technology is expected to detect neural signals with greater sensitivity, potentially enabling transvascular diagnosis and treatment of peripheral nervous system diseases for the first time, showcasing broad applicability across various indications.
- Initial Trial Focus: Currently, Autonomix's technology is primarily aimed at managing pain in pancreatic cancer, a condition that causes debilitating pain and lacks reliable solutions, indicating promising clinical application prospects for this technology.
- Broad Application Outlook: This technology platform is not limited to cancer pain management but may extend to cardiology, hypertension, and chronic pain management, demonstrating significant market potential and strategic importance for future growth.
See More
Autonomix Medical Releases Latest CEO Corner Segment
- Publication Strategy: CEO Brad Hauser emphasizes that over the past 12 to 18 months, Autonomix Medical has focused on expanding its scientific publication and presentation footprint by submitting clinical and technical data to competitive, peer-reviewed forums, thereby enhancing clinical credibility and laying a foundation for long-term growth.
- Innovative Technology Platform: The company's first-in-class platform technology includes a catheter-based microchip sensing array that may detect and differentiate neural signals with greater sensitivity than current technologies, potentially enabling transvascular diagnosis and treatment of peripheral nervous system diseases for the first time.
- Initial Trial Focus: Autonomix is initially developing this technology for treating pain associated with pancreatic cancer, a condition that causes debilitating pain and lacks reliable solutions, with initial trials paving the way for applications in cardiology, hypertension, and chronic pain management.
- Forward-Looking Statements: While Autonomix is optimistic about the potential effectiveness and clinical benefits of its nerve-targeted treatments, the company cautions investors about risks and uncertainties that could lead to significant differences between actual results and expectations, urging careful review of risk factors.
See More
Autonomix Medical to Present Long-Term Clinical Data at SSO 2026
- Clinical Data Presentation: Autonomix Medical will present long-term clinical data at the SSO Annual Meeting from March 5-7, 2026, where Clinical Development Engineer II Clarke Wilkirson, PhD, will highlight the potential of their minimally invasive transvascular RF energy-based ablation method in mitigating chronic pain for pancreatic adenocarcinoma patients.
- Technological Innovation: The company's first-in-class platform technology features a catheter-based microchip sensing array that may detect and differentiate neural signals with greater sensitivity than existing technologies, potentially enabling transvascular diagnosis and treatment of peripheral nervous system diseases for the first time.
- Industry Impact: The SSO Annual Meeting convenes leading surgical oncologists and researchers to showcase advancements in surgical oncology and emerging clinical technologies, and Autonomix's participation is expected to enhance its visibility and influence within the medical device industry.
- Market Potential: Currently, the technology is undergoing initial trials focused on pancreatic cancer, with plans to expand into cardiology, hypertension, and chronic pain management, indicating a broad market application potential.
See More
Autonomix Medical Announces 1-for-21 Reverse Stock Split
- Reverse Stock Split: Autonomix Medical has announced a 1-for-21 reverse stock split effective June 24, 2026, which will reduce outstanding shares from approximately 11.4 million to about 543,000, thereby increasing the market value per share and potentially boosting investor confidence.
- Trading Details: Post-split, the company's common stock will resume trading on the Nasdaq Capital Market under the existing ticker symbol 'AMIX' with a new CUSIP number 05330T304, ensuring a smooth transition for investors to the new capital structure.
- Shareholder Rights Protection: The split will not change the nominal par value per share, and no fractional shares will be issued; instead, shareholders entitled to fractional shares will receive cash compensation, safeguarding their interests during the transition.
- Innovation Context: Autonomix focuses on advancing innovative treatments for nervous system diseases, and the reverse split is expected to enhance the company's capital structure for future financing and technology development, thereby strengthening its competitive position in the medical device market.
See More
Autonomix Medical to Implement 1-for-21 Reverse Stock Split
- Reverse Stock Split Plan: Autonomix Medical will implement a 1-for-21 reverse stock split on June 24, 2026, which is expected to significantly enhance the stock price per share, thereby improving market perception of its stock.
- Reduction in Shares: Post-split, the outstanding shares will decrease from approximately 11.4 million to about 543,000, a change that will help improve earnings per share metrics and bolster investor confidence.
- Authorized Shares Unchanged: Despite the reduction in outstanding shares, the number of authorized common shares remains at 500 million, indicating that the company still has a substantial amount of unissued shares available for future financing or strategic purposes.
- Continued Nasdaq Trading: After the reverse split, AMIX shares will continue trading on Nasdaq under the same ticker symbol, which will help maintain investor recognition and market stability.
See More
Autonomix Releases Latest CEO Corner Segment Highlighting Clinical Recognition
- Growing Scientific Recognition: Since last fall, Autonomix has secured 13 abstract acceptances, including nine podium and four poster presentations, showcasing its nerve-sensing and transvascular denervation platform's recognition at global medical conferences, enhancing the company's reputation in the medical device sector.
- Award for Innovation: Autonomix received a top Cardiovascular Innovation Award at the Cardiovascular Research Technologies conference, highlighting the novelty, rigor, and potential impact of its technology platform, which further boosts the company's credibility in clinical applications.
- Transformative Treatment Potential: The company's real-time nerve sensing and targeted therapy approach could revolutionize treatment for complex conditions like pancreatic cancer pain, supporting physician adoption, future clinical trials, and strategic partnerships, thereby enhancing market competitiveness.
- Clinical Study Plans: Autonomix plans to conduct a clinical study in the U.S. aimed at addressing diagnostic and treatment challenges in nervous system diseases through its innovative technology, which is expected to create new growth opportunities for the company.
See More
Autonomix Medical Advances Cancer Pain Treatment Insights
- Clinical Data Significance: Autonomix Medical's clinical data presented at the Society of Surgical Oncology Annual Meeting was selected for podium presentation, highlighting its potential clinical impact on visceral cancer pain management, which may transform existing treatment practices.
- Platform Technology Potential: The company's microchip sensing array technology is expected to detect neural signals with greater sensitivity, potentially enabling transvascular diagnosis and treatment of peripheral nervous system diseases for the first time, showcasing broad applicability across various indications.
- Initial Trial Focus: Currently, Autonomix's technology is primarily aimed at managing pain in pancreatic cancer, a condition that causes debilitating pain and lacks reliable solutions, indicating promising clinical application prospects for this technology.
- Broad Application Outlook: This technology platform is not limited to cancer pain management but may extend to cardiology, hypertension, and chronic pain management, demonstrating significant market potential and strategic importance for future growth.
See More
Autonomix Medical Releases Latest CEO Corner Segment
- Publication Strategy: CEO Brad Hauser emphasizes that over the past 12 to 18 months, Autonomix Medical has focused on expanding its scientific publication and presentation footprint by submitting clinical and technical data to competitive, peer-reviewed forums, thereby enhancing clinical credibility and laying a foundation for long-term growth.
- Innovative Technology Platform: The company's first-in-class platform technology includes a catheter-based microchip sensing array that may detect and differentiate neural signals with greater sensitivity than current technologies, potentially enabling transvascular diagnosis and treatment of peripheral nervous system diseases for the first time.
- Initial Trial Focus: Autonomix is initially developing this technology for treating pain associated with pancreatic cancer, a condition that causes debilitating pain and lacks reliable solutions, with initial trials paving the way for applications in cardiology, hypertension, and chronic pain management.
- Forward-Looking Statements: While Autonomix is optimistic about the potential effectiveness and clinical benefits of its nerve-targeted treatments, the company cautions investors about risks and uncertainties that could lead to significant differences between actual results and expectations, urging careful review of risk factors.
See More
Autonomix Medical to Present Long-Term Clinical Data at SSO 2026
- Clinical Data Presentation: Autonomix Medical will present long-term clinical data at the SSO Annual Meeting from March 5-7, 2026, where Clinical Development Engineer II Clarke Wilkirson, PhD, will highlight the potential of their minimally invasive transvascular RF energy-based ablation method in mitigating chronic pain for pancreatic adenocarcinoma patients.
- Technological Innovation: The company's first-in-class platform technology features a catheter-based microchip sensing array that may detect and differentiate neural signals with greater sensitivity than existing technologies, potentially enabling transvascular diagnosis and treatment of peripheral nervous system diseases for the first time.
- Industry Impact: The SSO Annual Meeting convenes leading surgical oncologists and researchers to showcase advancements in surgical oncology and emerging clinical technologies, and Autonomix's participation is expected to enhance its visibility and influence within the medical device industry.
- Market Potential: Currently, the technology is undergoing initial trials focused on pancreatic cancer, with plans to expand into cardiology, hypertension, and chronic pain management, indicating a broad market application potential.
See More
